TechBio

Mental disorders account for one of the largest and fastest growing categories of the burden of disease worldwide. Mental ill-health has devastating effect on individuals, families and communities, and weighs heavily on societies and economies - the economic burden of mental ill-health can rise to up to 4% of GDP, and those with mental illness have poorer educational and work outcomes than those in good mental health. Psylo is building a proprietary platform for developing psychedelic medicines to redefine how we treat mental illness. The Psylo team is uniquely positioned to transform mental health treatment with the application of psychedelics. Collectively, they bring years of experience researching cannabinoids and building deep biotech companies. And, like all great company-builders, the founding team has assembled a supporting tribe of industry-leading biotech investors and psychedelic experts.

At the heart of the drug discovery and development process lies an indisputable truth: companies can test for many compounds but, in order to advance to further stages, they need to be able to manufacture it. Molecule.One is an AI-driven chemist that predicts the best possible synthetic pathways for any desired compound. Their software platform, powered by state-of-the-art machine learning models, discovers the cheapest and easiest way to synthesize any given compound from commercially available molecules. We’re excited to support the team as they build the future of chemistry.

Mass Dynamics' cloud-based software is designed from the bottom up for all the stakeholders in the project workflow: biologists, chemists, mass spec. experts and scientific report writers. There are two core features behind this initial version: a 'compute' module to run the massive data processing workflow, and a 'sharing and collaboration' module for teams to share insights and communicate.

Climate change is driving a transformative pivot in agriculture towards high-tech soilless greenhouses. These drastically reduce water use and emissions while significantly increasing yields. However, like humans need our gut microbiome, plants rely on the soil microbiome. This is missing in soilless agriculture, leading to reduced plant health and yield. Concert Bio addresses this by giving growers all the tools they need to create and manage an optimal microbiome in their system. Their proprietary platform gives growers unprecedented insights into their existing microbiome and uses that date to identify novel plant-beneficial microbes.

Chemify's technology enables the full stack digitization of chemistry from code to molecules and molecules to code for molecular discovery, optimization, and synthesis. They make the chemical synthesis of complex new molecules significantly faster, perfectly reproducible, and create large functional libraries of unprecedented scale.

Opto Bio is developing miniaturised implants that are safe, effective, and minimally invasive. Opto believes that that the application of discreet, safe biological interfaces will enable remote and continuous neurological communication, changing the way we approach medicine by using the electrical language of the body. Advancing the frontiers of biological interfacing, Opto is using new electrical biomarkers that can be used to inform disease state in real time. Opto aims to improve patient outcomes and revolutionise precision treatment through their research, development, and clinical testing.

Zafrens exists to bring the life sciences to the AI era using cutting edge engineering tools. The costs and pace of data generation in biology/chemistry lag behind our ability to process data by many, many orders of magnitude. Zafrens aim to bridge this gap by developing ultra-high throughput, ultra-high resolution approaches to studying cells, both at the single-cell level and in the context of cell-cell interactions in various co-cultures. Considering the quickest way to understand complex systems is to perturb them, and thus the team have built a versatile platform that allows us to probe profound, complex questions by simply swapping the inputs to the system.

Tetratherix has developed a proprietary, fully synthetic biomaterial that is compatible with minimally invasive administration techniques and does not induce any foreign body reaction, a genuine biostealth platform technology. The company has active development programs in the areas of regenerative medicine and mRNA delivery. Our world-leading team has spent a decade, inventing and developing the biomaterial technology and has proven its safety and efficacy as the world’s first biostealth matrix.